Commentary: Molecular testing in melanoma

作者: David M. Miller , Keith T. Flaherty , Hensin Tsao

DOI: 10.1016/J.JAAD.2014.01.866

关键词:

摘要: Insights into the underlying genetic and biologic drivers of melanoma their clinical consequences have developed at a vertiginous pace in last decade. Several key determinants tumor development progression emerged, including dysregulations p16:cyclin D-CDK4/6:RB pathway, alterations telomerase promoter, perturbations mitogenactivated protein kinase (MAPK) pathway. An appreciation complex interplay between immune system microenvironment importance molecules that govern checkpoint, such as cytotoxic T-lymphocyte antigen 4 programmed death 1/programmed ligand 1, has also developed. While this is undoubtedly an exciting time field, these important advances bring with them new challenges for clinician. Patients often inquire how seminal insights will affect outcome. Consequently, clinicians are beginning to field sophisticated questions regarding molecular testing melanoma, especially regards prognostic therapeutic implications those results. In issue Journal, Nagore et al further contextualize landscape by investigating significance BRAFmutations patients localized disease. Their report comes wake several studies explored profile BRAF mutations advanced commentary, we focus on few most common inquires faced clinic result investigations. Specifically, address question (‘‘Which should undergo testing?’’) followed natural corollaries (‘‘If patient testing, which tissue be sent, test used?’’). Lastly,

参考文章(45)
Roland Houben, Jürgen C Becker, Andreas Kappel, Patrick Terheyden, Eva-B Bröcker, Rudolf Goetz, Ulf R Rapp, Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. Journal of Carcinogenesis. ,vol. 3, pp. 6- 6 ,(2004) , 10.1186/1477-3163-3-6
Keith T. Flaherty, Jeffery R. Infante, Adil Daud, Rene Gonzalez, Richard F. Kefford, Jeffrey Sosman, Omid Hamid, Lynn Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini Kudchadkar, Howard A. Burris, Gerald Falchook, Alain Algazi, Karl Lewis, Georgina V. Long, Igor Puzanov, Peter Lebowitz, Ajay Singh, Shonda Little, Peng Sun, Alicia Allred, Daniele Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey Weber, Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations The New England Journal of Medicine. ,vol. 367, pp. 1694- 1703 ,(2012) , 10.1056/NEJMOA1210093
John A. Curtin, Klaus Busam, Daniel Pinkel, Boris C. Bastian, Somatic Activation of KIT in Distinct Subtypes of Melanoma Journal of Clinical Oncology. ,vol. 24, pp. 4340- 4346 ,(2006) , 10.1200/JCO.2006.06.2984
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott J. Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D. Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine. ,vol. 366, pp. 2443- 2454 ,(2012) , 10.1056/NEJMOA1200690
Helen Davies, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J. Garnett, William Bottomley, Neil Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian Parker, Claire Stevens, Stephen Watt, Steven Hooper, Rebecca Wilson, Hiran Jayatilake, Barry A. Gusterson, Colin Cooper, Janet Shipley, Darren Hargrave, Katherine Pritchard-Jones, Norman Maitland, Georgia Chenevix-Trench, Gregory J. Riggins, Darell D. Bigner, Giuseppe Palmieri, Antonio Cossu, Adrienne Flanagan, Andrew Nicholson, Judy W. C. Ho, Suet Y. Leung, Siu T. Yuen, Barbara L. Weber, Hilliard F. Seigler, Timothy L. Darrow, Hugh Paterson, Richard Marais, Christopher J. Marshall, Richard Wooster, Michael R. Stratton, P. Andrew Futreal, Mutations of the BRAF gene in human cancer Nature. ,vol. 417, pp. 949- 954 ,(2002) , 10.1038/NATURE00766
Daniel G Coit, Robert Andtbacka, Christopher J Anker, Christopher K Bichakjian, William E Carson, Adil Daud, Dominick DiMaio, Martin D Fleming, Valerie Guild, Allan C Halpern, F Stephen Hodi, Mark C Kelley, Nikhil I Khushalani, Ragini R Kudchadkar, Julie R Lange, Anne Lind, Mary C Martini, Anthony J Olszanski, Scott K Pruitt, Merrick I Ross, Susan M Swetter, Kenneth K Tanabe, John A Thompson, Vijay Trisal, Marshall M Urist, Nicole McMillian, Maria Ho, None, Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 395- 407 ,(2013) , 10.6004/JNCCN.2013.0055
Lars A. Akslen, Sabrina Angelini, Oddbjørn Straume, Ingeborg M. Bachmann, Anders Molven, Kari Hemminki, Rajiv Kumar, BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival Journal of Investigative Dermatology. ,vol. 125, pp. 312- 317 ,(2005) , 10.1111/J.0022-202X.2005.23788.X
David Z Chang, Katherine S Panageas, Iman Osman, David Polsky, Klaus Busam, Paul B Chapman, Clinical significance of BRAF mutations in metastatic melanoma. Journal of Translational Medicine. ,vol. 2, pp. 46- 46 ,(2004) , 10.1186/1479-5876-2-46
Kari Hemminki, Kamila Czene, Ilari Sauroja, Seppo Pyrhönen, Sabrina Angelini, Rajiv Kumar, Marjo Hahka-Kemppinen, BRAF Mutations in Metastatic Melanoma: A Possible Association with Clinical Outcome Clinical Cancer Research. ,vol. 9, pp. 3362- 3368 ,(2003)
S. Martín-Algarra, M. T. Fernández-Figueras, J. A. López-Martín, A. Santos-Briz, A. Arance, M. D. Lozano, A. Berrocal, J. J. Ríos-Martín, E. Espinosa, J. L. Rodríguez-Peralto, Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical & Translational Oncology. ,vol. 16, pp. 362- 373 ,(2014) , 10.1007/S12094-013-1090-5